Free Testing For Covid-19 Is Out Of The Question, Says Thyrocare’s A Velumani
Free testing for Covid-19 will not be feasible due to higher costs, according to Thyrocare Technologies Ltd.'s A Velumani.
“Doing tests for free is out of question. This is not a routine test, it costs around Rs 10,000-12,000 on a commercial scale,” Velumani, managing director of company, told BloombergQuint in an interview. Tests could be done at a subsidies rate though, he said.
That comes when the Indian Council of Medical Research has appealed to private laboratories to offer the Covid-19 testing free of cost.
Health laboratories performing Covid-19 testing of respiratory specimens are provided the reagents from the U.S.-based International Reagent Resource, he said, adding that there are challenges in terms of reagent costs and specimen collection.
Velumani said Thyrocare has not been roped in by the government as of now, though the diagnostic company has been in talks with them informally.
There are 72 functional government-run laboratories for testing and 49 more will be active by the end of the month, according to Balram Bhargava, director general of Indian Council of Medical Research.
But even then the tests are not adequately done, Velumani said. “Whether it's because the demand is low or whether the people don't want to go to a government hospital or the government putting many conditions is not clear.”
Velumani, however, said hospitals will have an upper hand at doing tests than standalone diagnostic centers. Tests can be scaled up to 500 per center per day, he said.
Watch the video here:
-
Where You Live Shapes How You Get To Work | The Reason Why
Two-wheelers are the most popular way to get to work in India, accounting for nearly 43% of workplace commutes.
-
High US Salaries, No Green Card Certainty: The Financial Calculation Facing Indian H-1B Families
The suspension of PERM processing at eight technology employers does not cancel existing H-1B visas. What it does is force a question many Indian families have been avoiding: is the US salary worth tying your career and family plans to one employer?
-
Unhedged Position: Can India See An Indonesia-Style Time Correction?
The Nifty is trading below levels it first clocked in 2024. Is there, then, as I have suggested in the headline, potential that the current time correction drags on painfully for the next three-five, even ten years?
-
Navigating Friction And Energy Realities: An Analysis Of Marco Rubio's October Visit To India
Occurring at a critical juncture marked by stalled trade negotiations and escalating geopolitical pressures over global energy supplies, the visit offers a profound window into modern US-India relations.
-
India Exports Capital. Why Not Export Trusteeship?
The big question, then, is whether India can build an institution that global borrowers, investors, banks, and lawyers can trust, even without an Indian connection.
-
France's Economy & Politics Are In Crisis | The Reason Why
Let's look at how the French economy and politics evolved under Nicolas Sarkozy, Franois Hollande and Emmanuel Macron.
-
You May Inherit The Business. You Must Earn Its Credibility.
Succession tests the founder's ability to share authority as much as it tests the next generation's readiness to assume it.
-
Signing Deals Is One Thing; Making Them Work Is Another | The Week In Whys
Sometimes, things don't turn out as planned. Indian companies have lost some bids to rivals, some projects won't produce until 2030.
-
FOMC Wall, PERM Suspension, Hospital Stocks | Talking Points This Week
A PERM suspension would directly affect green-card sponsorship rather than H-1B visas, so the near-term earnings impact could remain relatively limited. The key question is whether this marks a new phase in US scrutiny of Indian IT.
-
Everything, Everywhere, All At Once: Dalal Street's Week To Forget | Joining The Dots
Visa curbs, a Starlink spat and cancer drug caps: what connects this week's shocks for Indian markets